These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12362253)

  • 1. Is the poor recovery of commercial recombinant factors VIII and IX caused by damage from monoclonal antibody purification?
    Shanbrom E
    Thromb Haemost; 2002 Oct; 88(4):700. PubMed ID: 12362253
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine.
    Feldman F; Chandra S; Huang C
    Acta Haematol; 1995; 94 Suppl 1():25-32; discussion 33-4. PubMed ID: 7571992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern treatment of hemophilia: from the shadows towards the light.
    Mannucci PM
    Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096
    [No Abstract]   [Full Text] [Related]  

  • 4. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 5. Whole blood collection using metered anticoagulation for production of Factor VIII and Factor IX.
    Penny A; Pinner M; Townley A; Mosley P; Smith J; Lane R; Munford C; Robinson A
    Prog Clin Biol Res; 1990; 337():487-9. PubMed ID: 2112756
    [No Abstract]   [Full Text] [Related]  

  • 6. [The current therapeutic bases for hemophilia].
    Négrier C
    Transfus Clin Biol; 2000 Jun; 7(3):257-8. PubMed ID: 10919215
    [No Abstract]   [Full Text] [Related]  

  • 7. [Isolation of blood coagulation factors (VII, VIII and IX)].
    Dzegilenko NB
    Gematol Transfuziol; 1990 May; 35(5):38-40. PubMed ID: 2118467
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 9. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
    Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
    Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
    [No Abstract]   [Full Text] [Related]  

  • 10. Recommendations of the subcommittee on human factor VIII (AHF) and factor IX (PTC) preparations.
    Wagner RH
    Thromb Diath Haemorrh Suppl; 1968; 35():235-7. PubMed ID: 5761065
    [No Abstract]   [Full Text] [Related]  

  • 11. [Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].
    Kamiya T
    Rinsho Ketsueki; 1988 May; 29(5):666-70. PubMed ID: 3145998
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.
    Ragni MV
    Drugs; 2015 Sep; 75(14):1587-600. PubMed ID: 26310188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chamber of hope for hemophilia.
    Pipe SW; Kaufman RJ
    Nat Biotechnol; 2000 Mar; 18(3):264-5. PubMed ID: 10700134
    [No Abstract]   [Full Text] [Related]  

  • 16. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 17. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
    Oh HK; Lee JM; Byun TH; Park SY; Kim YH
    Biotechnol Prog; 2001; 17(6):1119-27. PubMed ID: 11735450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Conditions for obtaining hemostatic preparations from donor plasma].
    Kunakova NV; Diakonova SF; Rusanov VM; Rudnitskaia MZ
    Gematol Transfuziol; 1989 Oct; 34(10):40-2. PubMed ID: 2515092
    [No Abstract]   [Full Text] [Related]  

  • 19. Chairman's Introductory remarks.
    Shulman NR
    Ann N Y Acad Sci; 1975 Jan; 240():7. PubMed ID: 1053888
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro carboxylation of a blood coagulation factor IX precursor produced by recombinant-DNA technology.
    Soute BA; Balland A; Faure T; de la Salle H; Vermeer C
    Thromb Haemost; 1989 Apr; 61(2):238-42. PubMed ID: 2749597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.